ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome
-
By
-
Chen Li
-
Zhichao Yang
-
Jialei Zhang
-
Xiaodong Yan
-
Hongwei Su
-
May 28, 2026
-
Clinical Scorecard: ADGRD1 Enhances Bladder Cancer Advancement and Angiogenesis Through the PI3K/AKT/mTOR Pathway-Driven Pro-Angiogenic Secretome
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | ADGRD1 activates the PI3K/AKT/mTOR signaling pathway. |
| Target Population | |
| Care Setting | |
Key Highlights
- ADGRD1 expression correlates with advanced-stage and high-grade BLCA.
- ADGRD1 serves as a predictor of poor overall survival and progression-free interval.
- ADGRD1 promotes proliferation, migration, invasion, and angiogenesis in BLCA.
- Inhibition of PI3K/AKT/mTOR reverses the oncogenic effects of ADGRD1.
Guideline-Based Recommendations
Diagnosis
Management
- Targeting the PI3K/AKT/mTOR pathway in advanced BLCA therapies should be directly sourced.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Pharmacological inhibition of the PI3K/AKT/mTOR pathway may be explored.
Clinical Best Practices
- Assess ADGRD1 expression for prognostic evaluation in BLCA.
Related Resources & Content
